These new recommendations are following the text published in 2004 by the group of experts of the EFSUMB that was augmented to reevaluate the indications of ultrasound contrast agents. Initially limited to focal liver lesions, new recommendations include the study of renal and pancreatic diseases, as well as vesico-ureteric reflux, blunt abdominal trauma and trans-cranial Doppler. Contrast-enhanced ultrasound improves the diagnosis of renal pseudo-tumors but does not allow characterization of solid focal masses. Its major contribution includes characterization of complex cystic masses, diagnosis of peripheral vascular disorders such as infarction and cortical necrosis, and radiofrequency ablation follow-up. It is also useful for the study of pancreatic masses visible at ultrasound in order to improve lesion visualization and characterization (adenocarcinoma and neuro-endocrine tumors), as well as for vascular staging.